Zimmer Biomet Holdings Contingent consideration (receivable) payable - financing activities increased by 807.9% to $69.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 296.6%, from $17.40M to $69.00M.
klac_contingent_consideration_financing| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '23 | Q2 '23 | Q1 '24 | Q3 '24 | Q1 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $700.00K | $0.00 | $2.40M | $9.60M | $700.00K | $1.50M | $2.00M | $17.40M | $7.60M | $69.00M |
| QoQ Change | — | -100.0% | — | +300.0% | -92.7% | +114.3% | +33.3% | +770.0% | -56.3% | +807.9% |
| YoY Change | — | — | — | — | — | -84.4% | — | >999% | +280.0% | +296.6% |